Zenflow has raised $52m in a round led by Cook Medical to accelerate the commercialisation of its implant for an enlarged prostate, with Cook also coming on board to lead US distribution activities for the device.
Proceeds from the oversubscribed Series D financing round will support Zenflow’s commercialisation activities around the device, called Spring. The nitinol-based implant gets inserted into the urethra and is designed to provide relief from obstructive lower urinary tract symptoms secondary to benign prostatic hyperplasia (BPH) while preserving sexual function — a key differentiator in the BPH treatment landscape, according to Zenflow. Spring obtained US Food and Drug Administration (FDA) clearance in December 2025.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
According to the California-based company, its device, which is implantable during an office-based procedure, opens a new category of treatment it refers to as first-line interventional therapy (FIT), a protocol that gives physicians a device-based option instead of drug therapy for secondary BPH symptoms.
Alongside Cook Medical’s lead role in Zenflow’s latest financing round, the company has also inked an exclusive US distribution agreement for the device, complementing its existing portfolio of prostate health products.
“BPH is one of the most prevalent conditions affecting men’s quality of life, and yet many patients remain undertreated or dissatisfied with existing options,” said Johan Lowinger, director of product management for Cook Medical’s urology speciality.
“The Zenflow Spring represents exactly the kind of breakthrough we look for — a simple, effective, office-based solution that puts patients first. We are excited to bring this technology to urologists and their patients through our distribution network,” Lowinger continued.
BPH, typically affecting men aged 50 and above, causes the enlarged prostate to press on the urethra, making it harder to urinate and leading to symptoms that disrupt quality of life, including difficulty starting or fully emptying the bladder, a weak or interrupted stream, increased frequency and urgency. Research indicates that around 50% of men between the ages of 51 and 60 have BPH, with this figure rising to 70% among men aged 60 to 69 and around 80% of men over 70 years of age.
Commenting on Cook’s new role as US distributor for Spring, Zenflow’s CEO, Shreya Mehta, said: “Cook Medical’s deep relationships within urology and proven commercialisation capabilities make them the ideal partner to help bring the benefits of the Zenflow Spring to patients across the country.”
